Radio-Guided Surgery with a New-Generation β-Probe for Radiolabeled Somatostatin Analog, in Patients with Small Intestinal Neuroendocrine Tumors

What Was Tested

The paper reports a study of Octreotide and Somatostatin, published as a clinical trial, phase ii.

The researchers aimed to assess the sensitivity (SE) and SP of the intraoperative RGS approach using a β-probe with a per-lesion analysis, while assessing safety and feasibility as secondary objectives.

Why It Was Studied

68Ga-DOTATOC Radio-Guided Surgery with β-Probe in GEP-NET (RGS GEP-NET) [NCT0544815; https://classic.

Who Took Part

The study group was 20 patients.

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

This prospective, single-arm, single-center, phase II trial (NCT05448157) enrolled 20 patients diagnosed with small intestine NETs (SI-NETs) with positive lesions detected at 68Ga-DOTA-TOC positron emission tomography/computed tomography (PET/CT).

In vivo measurements were conducted using a β-probe.

How the Study Was Run

Receiver operating characteristic (ROC) analysis was performed, with the tumor-to-background ratio (TBR) as the independent variable and pathology result (cancer vs. non-cancer) as the dependent variable.

What Was Measured

PubMed files the paper under topics including Neuroendocrine Tumors, Intestinal Neoplasms, Radiopharmaceuticals, Positron Emission Tomography Computed Tomography, Intestine, Small, Octreotide and Surgery, Computer-Assisted.

The authors tagged it with the keywords 68Ga-DOTA-TOC, Lymph-node metastases, Radical surgery, Radio-guided surgery and β-probe.

What This Means in Plain Language

This is a clinical trial, phase ii of Octreotide and Somatostatin in 20 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2024 (Annals of surgical oncology), a journal based in United States.

More context: the Octreotide compound page and the Somatostatin compound page, all human trials.